Cemiplimab, a PD-1 inhibitor, exhibited substantial enhancements in OS and PFS compared to chemotherapy in advanced NSCLC patients with PD-L1 expression of at least 50%, offering a potential novel treatment for these patients (52, 54). Here, PDCD1 is linked to non-small cell lung carcinoma.